Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00048425 | Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure. | PHASE3 | COMPLETED | 600 | — | — | Sep 1, 2002 | Dec 1, 2004 | Dec 15, 2006 | 166 | United States, Australia +2 |
| Name | Type | Description |
|---|---|---|
| Levosimendan | DRUG | - |
Inclusion Criteria: * A written informed consent must be obtained for hospitalized male or female patients over 18 years old of age. * The eligible patients must be diagnosed with worsening heart failure as evidenced by dyspnea at rest, poor ejection fraction and have been treated with IV diuretics...